NCER Comments: Both ongoing studies and limited clinical use show promising results for REGN-CoV2 therapy. No aborted fetal tissue was used in the creation of Regeneronʼs COVID-19 and no fetal tissue is contained in the therapy. Two sources of antibodies were used: human and mice. The company has filed for “expanded access” from the FDA, and an Executive […]